Home / Products
Bashir™ Endovascular Catheters
Watch to learn about BASHIR™ Endovascular Catheter's exclusive features.
Riyaz Bashir, MD, FACC, RVT, Professor of Medicine for the Lewis Katz School of Medicine at Temple University, (Philadelphia, PA) and Director of Vascular and Endovascular Medicine at Temple University Hospital, created Bashir Endovascular Catheters to dissolve large blood clots quickly and effectively, to improve the quality of life for patients suffering from venous thromboembolic (VTE) conditions.
In his words, “VTE has become a significant health concern in the U.S…causing up to 100,000 deaths each year. My inspiration was to develop a device that would provide better treatment outcomes by enhancing both endogenous and exogenous fibrinolysis.”
BASHIR™ endovascular catheters are the ﬁrst interventional catheters to rapidly create multiple channels so the patient’s own endogenous lytics can ﬂow into the culprit thrombus.
VTE is an under-recognized and under-treated condition: it’s the third leading cause of cardiovascular related death.
How the BASHIR™ endovascular catheter works
Immediately forms a large central channel for blood flow through a clot when the mini-infusion catheters are expanded.
Creates a series of cross-sectional channels through the occlusive thrombus, permitting the patient’s own blood flow and its endogenous lytics to dissolve the clot.
Permits infusion of fluids including exogenous lytics to saturate the clot through its 6 mini-infusion catheters with 48 precision-drilled holes intended to synergistically enhance the efficiency of the therapy.
How We're Different
The Proof of Principle Study in a model of thrombosis in the vena cava, using the BASHIR™ endovascular catheter with the administration of r-tPA, resulted in 80% lysis of a 30cc clot burden in only 4 hours.
BASHIR™ Endovascular Catheters should play a key role in improving the quality of life for patients suffering from VTE conditions.
Need more details? Contact us.
We are here to assist. Contact us by phone, email or via our social media channels.